Beyond Biotech Podcast

About Beyond Biotech podcast – the podcast from Labiotech.eu

Welcome to Beyond Biotech podcast! This is the official podcast of Labiotech.eu. Each week, our journalists talk about what is happening in the world of biotech with interviews to the top industry experts and authorities. Join us as we deep dive into the most impactful news on topics like clinical trials, drug discovery, mergers and acquisitions, and more!

A new podcast episode is available every Friday.

About Beyond Biotech podcast – the podcast from Labiotech.eu

A new podcast episode is available every Friday.

Listen to Beyond Biotech:

induced pluripotent stem cells ipsc Alzheimer's

Podcast 20 Oct 2023

Beyond Biotech podcast 68 – rejuvenation with stem cells

This week, our guest on the podcast is Mark Kotter, founder of clock.bio. clock.bio, a sister company to bit.bio, which Kotter also founded and is the CEO of, aims to extend and improve quality of life by reversing the harmful effects of time in our cells, harnessing the regenerative capabilities of human pluripotent stem cells […]

October 20, 2023

Podcast 13 Oct 2023

Beyond Biotech podcast 67 – natural killer cells

This week, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August, the company announced FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell […]

October 13, 2023

Podcast 6 Oct 2023

Beyond Biotech podcast 66 – treating rare diseases with tRNA

Compared to the smallest mRNA molecule, which is 300 nucleotides long, the largest transfer RNAs (tRNA) is less than a third of the size at 76 nucleotides. Scientists at Alltrna are harnessing the unique biology of tRNAs to engineer a single tRNA medicine that could treat thousands of rare diseases that share the same genetic […]

October 6, 2023

Podcast 29 Sep 2023

Beyond Biotech podcast 65 – Disease X and pandemic preparedness

Disease X, a concept shrouded in mystery, represents the unknown pathogens that could unleash future epidemics or pandemics. In the wake of recent global health crises, our understanding of the profound impact of those pandemics has deepened. On this week’s podcast, we have a conversation with Hamilton Bennett, who led Moderna’s mRNA-1273 COVID-19 vaccine development […]

September 29, 2023

Podcast 22 Sep 2023

Beyond Biotech podcast 64 – Precision immuno-oncology therapies

Despite the huge commercial success of PD-1 inhibitors and widespread use of checkpoint inhibitors such as anti-PD-1 or anti-CTLA4, 70 to 80% of patients still experience limited or no response to existing therapies. In response to this critical challenge, Portage Biotech is on a mission to expand the number of patients who derive long-term […]

September 22, 2023

Podcast 15 Sep 2023

Beyond Biotech podcast 63 – Fighting cancer with STRIs

This week’s podcast is sponsored by Vetter. On this week’s episode, we have a conversation with Steve Worland, CEO of eFFECTOR Therapeutics. eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of cancer drugs referred to as STRIs (selective translation regulation inhibitors). eFFECTOR’s STRI product candidates target the eIF4F complex and […]

September 15, 2023

Podcast 8 Sep 2023

Beyond Biotech podcast 62 – cytokine-based drugs

As September 8 is Stand Up To Cancer Day, one area of promising research lies in cytokine-based drugs, which have the potential to activate T cells against tumors. Historically, toxicity from systemic cytokine treatment has remained a challenge, prompting several companies to explore ways to “engineer” drugs with modified cytokine molecules like interleukin 2 (IL-2) […]

September 8, 2023

Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed’s CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which […]

September 1, 2023

Podcast 25 Aug 2023

Beyond Biotech podcast 60 – The cost of research

On this week’s podcast, we have a conversation with Dr Jack Scannell, CEO of Etheros Pharmaceuticals Corp. Scannell recently co-authored a paper on the expenses related to clinical research and the factors that underly the translational failure of inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) in oncology. Costs and Causes of Oncology Drug Attrition […]

August 25, 2023

Podcast 18 Aug 2023

Beyond Biotech podcast 59 – World Lung Cancer Day

Since its inception in 2012, World Lung Cancer Day has been observed every year on August 1 in order to raise awareness of lung cancer issues and magnify the need for more lung cancer research funding. Around a quarter of a million people in the US alone will be diagnosed with some form of lung […]

August 18, 2023

Podcast 11 Aug 2023

Beyond Biotech podcast 58 – Pepteins

To learn about pepteins, we had a conversation with Christian Schwarz, CEO and co-founder of Numaferm. Numaferm is a German biotech company, specializing in the production of pepteins, which are an underdeveloped class of molecules located between peptides and proteins (with a length of 30-300 amino acids). Pepteins are non-structured and complex posing a […]

August 11, 2023

Podcast 4 Aug 2023

Beyond Biotech podcast 57: Group B Strep

To recognize International Group B Strep Awareness Month in July, we had a conversation with MinervaX CEO, Per Fischer. MinervaX is a privately-held Danish biotechnology company developing a novel prophylactic vaccine against Group B streptococcus (GBS), with two phase II clinical trials ongoing in pregnant women and a phase I clinical trial ongoing in older adults. Due […]

August 4, 2023

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 biotech companies to watch in 2025

Biotech in 2024: A retrospective

Grab your free report on 3D organoids and explore their future potential

Five biosimilar companies you should know about

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!